English | Español

Pharmaceuticals

+ Pharmaceuticals
Patient Daily | Jul 28, 2026

Altimmune’s GLP-1/GIP drug reduces heavy drinking in Phase 2 alcohol use disorder trial
+ Pharmaceuticals
Patient Daily | Jul 28, 2026

Researchers identify key barrier preventing self repair of heart cells
+ Pharmaceuticals
Patient Daily | Jul 28, 2026

Study reveals how gum disease drives systemic inflammation
+ Pharmaceuticals
Patient Daily | Jul 28, 2026

Study finds blood test may improve early detection of tuberculosis
+ Pharmaceuticals
Patient Daily | Jul 28, 2026

Curtin University study finds preschool attendance boosts school readiness in Western Australia
+ Pharmaceuticals
Patient Daily | Jul 28, 2026

ACAAI outlines steps for back-to-school allergy and asthma management
+ Pharmaceuticals
Patient Daily | Jul 28, 2026

FDA raises concerns over Replimune’s melanoma drug data ahead of advisory meeting
+ Pharmaceuticals
Patient Daily | Jul 28, 2026

American Lung Association launches campaign on COVID-19 therapeutic options for providers

Trending
+ Pharmaceuticals
Patient Daily | Aug 6, 2026

FDA approves Replimune’s melanoma drug Tudriqev after advisory committee debate
+ Pharmaceuticals
Patient Daily | Aug 4, 2026

Merck reports mixed results for tulisokibart in recent clinical trials and financial update
+ Regulatory
M. Y. Bailey | Aug 7, 2026

PhRMA's Zirkelbach: 340B program has changed dramatically with 'little transparency into how patients benefit'
Patient Daily reports | Aug 10, 2026

SoCal Breathe Free warns persistent sinus symptoms may signal chronic inflammation